Form 4: Apellis Pharmaceuticals Acquired by Biogen

Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus a contingent value right.

Summary

• Apellis Pharmaceuticals, Inc. has completed its merger with a subsidiary of Biogen Inc.
• Shareholders receive $41.00 per share in cash plus one non-transferable contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 per share upon the achievement of specific milestones.
• All outstanding equity awards, including RSUs and stock options, were converted into cash and/or CVRs based on the merger terms.
• The company is now a wholly owned subsidiary of Biogen.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the acquisition provides immediate liquidity at a defined price with potential upside through CVRs.

Positives

• Shareholders receive a guaranteed cash payment of $41.00 per share.
• Potential for additional upside of up to $4.00 per share through contingent value rights.
• Successful completion of the merger process as of May 14, 2026.

Negatives

• The company ceases to exist as an independent publicly traded entity.
• Options with exercise prices of $45.00 or higher were cancelled without consideration.
• CVR payments are contingent on future milestones and are not guaranteed.

Risks

• Failure to achieve the milestones required for the CVR payout.
• Tax withholding implications on the cash consideration received by shareholders.
• Integration risks associated with becoming a subsidiary of Biogen.

Future Outlook

The company is now a wholly owned subsidiary of Biogen, and future performance is subject to the terms of the CVR agreement and Biogen's integration strategy.

Management Comments

• The compensation committee certified that the Relative TSR as of May 8, 2026, was at the 93.3rd percentile, resulting in a 200% payout for applicable RSUs.

Industry Context

StockSavvy.ai notes that this acquisition represents a significant consolidation in the biotechnology sector, reflecting Biogen's strategic interest in expanding its pipeline through the acquisition of Apellis's assets.

Comparison to Industry Standards

• The use of CVRs is a standard mechanism in biotech M&A to bridge valuation gaps regarding clinical trial outcomes.
• The $41.00 cash offer represents a premium typical for mid-cap biotech acquisitions.

Stakeholder Impact

• Shareholders receive cash and CVRs.
• Employees and management transition to Biogen ownership.
• The company is no longer a standalone public entity.

Next Steps

• Achievement of milestones defined in the CVR agreement.
• Potential future payments to former shareholders if milestones are met.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Contingent Value Right, Tender Offer